What is Lovenox?
Lovenox is the brand name for enoxaparin sodium, an anticoagulant that prevents clots from forming in the veins. It inhibits clotting factors to cut the chance of clot formation. It prevents deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients at risk from surgery, bed rest, or other conditions, and it treats DVT and PE that have already happened. It also prevents clots in patients with unstable angina or non-Q wave myocardial infarction. It is given by subcutaneous injection, with dose and duration set by the patient's condition and response. Side effects include bleeding, bruising, and pain or irritation at the injection site.
Generic Name
enoxaparin sodium
Brand Names
Lovenox (United States and Canada), Clexane (Europe, Asia, and Latin America), Xaparin (Australia), Enoxaparin Winthrop (Australia), Enoparin (India).
Drug Classification
Therapeutic class: anticoagulants. Pharmacologic class: antithrombotics.
Indications and Therapeutic Effects
Deep vein thrombosis (DVT): prevention of clots in the veins, usually the legs. Pulmonary embolism (PE): treatment or prevention of a clot blocking a lung vessel. Unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI): used with other medications. ST-segment elevation myocardial infarction (STEMI): used with other medications. Prevention of clots during hip or knee replacement surgery, abdominal surgery, or in patients at high risk of clotting.
Mechanism of Action
Enoxaparin inhibits Factor Xa, a key step in the clotting cascade, which reduces the conversion of prothrombin to thrombin and prevents clot formation. It is a low molecular weight heparin (LMWH), so its smaller molecular size lets it penetrate vessel walls and absorb more reliably than unfractionated heparin. That cuts the risk of DVT, PE, and certain cardiac conditions.
Precautions and Contraindications
Precautions
Use caution with a history of bleeding disorders, uncontrolled hypertension, or recent stroke. Use caution in elderly and debilitated patients, who bleed more easily. Use caution with kidney or liver problems, which also raise bleeding risk. Do not use with an active bleeding disorder or a known allergy to heparin or any component. Use caution with other drugs that raise bleeding risk, such as NSAIDs, aspirin, or anticoagulants like warfarin.
Contraindications
Heparin-induced thrombocytopenia (HIT), a serious reaction to heparin that drops the platelet count. Active or recent major bleeding, such as GI bleeding or hemorrhagic stroke. Bacterial endocarditis. Spinal anesthesia or spinal puncture, where it can cause bleeding into the spinal cord.
Drug Interactions
Drug-Drug
Other blood thinners (warfarin, aspirin, NSAIDs) raise bleeding risk. Other forms of heparin raise bleeding risk. Thrombolytics raise bleeding risk. SSRIs and SNRIs raise bleeding risk. NSAIDs such as ibuprofen or naproxen raise bleeding risk. Antiplatelet drugs such as clopidogrel or ticlopidine raise bleeding risk. Digoxin levels can climb toward toxicity, causing nausea and vomiting.
Drug-Natural Products
Garlic, ginger, ginkgo biloba, high-dose vitamin E, fish oil, danshen, dong quai, and saw palmetto all raise bleeding risk when taken with Lovenox.
Drug-Food
No known significant drug-food interactions. Keep a healthy, balanced diet to support overall health.
Adverse Effects
Bleeding (gums, nosebleeds, bruising), the main risk. Injection site reactions such as pain, bruising, or redness. Allergic reactions ranging from mild to severe (hives, itching, swelling, difficulty breathing, chest pain). Thrombocytopenia, a drop in platelets that can mean more bleeding or bruising. Osteoporosis with long-term use. Nausea or vomiting. Diarrhea. Headache.
Administration Considerations
Available Forms
- Solution for injection (prefilled syringes): 30 mg/0.3 mL, 40 mg/0.4 mL, 60 mg/0.6 mL, 80 mg/0.8 mL, 100 mg/1 mL, 120 mg/0.8 mL, 150 mg/mL.
Dosage for Adults
- Subcut (Adults)
- VTE prophylaxis in patients undergoing knee replacement surgery, 30 mg q 12 hr starting 12-24 hr postop for 7-10 days.
- VTE prophylaxis in patients undergoing hip replacement surgery, 30 mg q 12 hr starting 12-24 hr postop or 40 mg once daily starting 12 hr before surgery (either dose may be continued for 7-14 days; continued prophylaxis with 40 mg once daily may be continued for up to 3 wk).
- VTE prophylaxis following abdominal surgery, 40 mg once daily starting 2 hr before surgery and then continued for 7-12 days or until ambulatory (up to 14 days).
- VTE prophylaxis in medical patients with acute illness, 40 mg once daily for 6-14 days.
- Treatment of DVT/PE (outpatient), 1 mg/kg q 12 hr. Warfarin should be started within 72 hr; enoxaparin may be continued for a minimum of 5 days and until therapeutic anticoagulation with warfarin is achieved (INR >2 for 2 consecutive days).
- Treatment of DVT/PE (inpatient), 1 mg/kg q 12 hr or 1.5 mg/kg once daily. Warfarin should be started within 72 hr; enoxaparin may be continued for a minimum of 5 days and until therapeutic anticoagulation with warfarin is achieved (INR >2 for two consecutive days).
- Unstable angina/non-ST-segment-elevation MI, 1 mg/kg q 12 hr for 2-8 days (with aspirin).
- IV, Subcut (Adults <75 yr)
- Acute ST-segment-elevation MI, administer single IV bolus of 30 mg plus 1 mg/kg subcut dose (maximum of 100 mg for first 2 doses only), followed by 1 mg/kg subcut q 12 hr. The usual duration of treatment is 2-8 days. In patients undergoing percutaneous coronary intervention, if last subcut dose was <8 hr before balloon inflation, no additional dosing needed; if last subcut dose was ≥8 hr before balloon inflation, administer single IV bolus of 0.3 mg/kg.
- Subcut (Adults ≥75 yr)
- Acute ST-segment-elevation MI, 0.75 mg/kg every 12 hr (no IV bolus needed) (maximum of 75 mg for first 2 doses only; no initial bolus). The usual duration of treatment is 2-8 days.
Renal Impairment
- Subcut (Adults CCr <30 mL/min)
- VTE prophylaxis for abdominal or knee/hip replacement surgery, 30 mg once daily. Treatment of DVT/PE, 1 mg/kg once daily.
- Unstable angina/non-ST-segment-elevation MI, 1 mg/kg once daily.
- Acute ST-segment-elevation MI (patients <75 yr), single IV bolus of 30 mg plus 1 mg/kg subcut dose, followed by 1 mg/kg subcut once daily.
- Acute ST-segment-elevation MI (patients ≥75 yr), 1 mg/kg once daily (no initial bolus).
Pharmacokinetics
Given subcut, enoxaparin is rapidly and completely absorbed, with peak blood concentrations within four hours and bioavailability near 100%. It distributes in the blood and extravascular fluid, does not cross the blood-brain barrier, and has a volume of distribution of approximately 5-7 liters in healthy adults. It is metabolized in the liver by heparinase and heparinase-like enzymes and, unlike unfractionated heparin, does not require antithrombin III to work. About 10% is excreted unchanged in the urine and the remaining 90% is metabolized and eliminated in the feces; clearance falls in renal impairment, raising bleeding risk. Elimination half-life is approximately four hours; the enoxaparin half-life runs 3-6 hr and increases in renal insufficiency.
Nursing Considerations for Lovenox
Nursing Assessment
Review the medical history, especially bleeding or clotting disorders, recent surgery, or trauma, since these affect safety and effectiveness. Monitor vital signs (blood pressure, pulse, oxygen saturation) before and after dosing, since changes may signal an adverse reaction. Inspect the injection site for bleeding, bruising, redness, or swelling, and note pain or discomfort that may mean inflammation or infection. Assess bleeding risk, including drugs or conditions that add to it (anticoagulant therapy, liver or kidney disease, recent surgery). Watch for allergic reaction (itching, hives, rash, shortness of breath, or swelling of the face, lips, tongue, or throat); stop the drug and notify the provider if it occurs. Monitor CBC and platelet count regularly, especially with prolonged use, since changes may signal an adverse reaction. Assess the patient's understanding of Lovenox and teach self-injection if they will dose at home. Assess for constipation and intervene with fiber, hydration, and stool softeners or laxatives as ordered.
Nursing Diagnosis
Risk for bleeding related to the anticoagulant effect and the patient's history. Risk for injury related to bleeding or hematoma at the injection site. Risk for infection related to improper injection technique or poor hygiene, with knowledge deficit about dosing, administration, and side effects. Impaired physical mobility related to bedrest or immobilization, which raises DVT and PE risk. Anxiety related to the need for anticoagulant therapy and possible complications, with ineffective regimen management from difficulty self-injecting or inadequate followup. Impaired skin integrity related to ecchymosis or hematoma at the injection site. Constipation related to immobility or changes in diet and fluid intake. Risk for ineffective tissue perfusion related to arterial or venous thrombosis.
Nursing Interventions
Give Lovenox as prescribed, following the orders for dose, route, and timing. Clean the injection site and inject subcutaneously at a 90-degree angle. For toxicity or overdose, give protamine sulfate 1 mg for each mg of enoxaparin by slow IV injection, recognizing that this reverses only part of the anticoagulant effect (StatPearls). Routine coagulation monitoring is not needed, but when a level is required (renal impairment, obesity, pregnancy), draw an anti-Factor Xa level about 4 hours after the dose rather than an aPTT (StatPearls). Promote mobility, encouraging the patient to move to prevent DVT and PE. Assist with range-of-motion exercises if the patient is bedridden, to prevent clots, keep joints flexible, and limit muscle atrophy. Provide emotional support, addressing concerns about therapy and complications.
Intravenous Administration
IV push (for STEMI only): inject via IV line. Flush with 0.9% NaCl or D5W before and after to avoid mixing with other drugs and to clear the port. May be given with 0.9% NaCl or D5W. Rate: inject as a bolus. Y-site incompatibility: do not mix or co-administer with other medications.
Patient Education and Teaching
Explain why the patient is on Lovenox, how it works, and how it prevents clots. Teach proper administration and the dosing schedule, plus safe disposal of used needles and syringes. Teach injection site care: clean the site and rotate sites to prevent tissue damage, infection, bleeding, and bruising. Report unusual bleeding or bruising, dizziness, itching, rash, fever, swelling, or difficulty breathing to the provider immediately. Do not take aspirin or NSAIDs without checking with the provider, since they raise bleeding risk. Make lifestyle changes such as avoiding activities that raise bleeding or injury risk, eating well, and quitting smoking. Keep all followup appointments for monitoring and dose adjustment.
Evaluation and Desired Outcomes
Prevention of DVT and PE, lowering the risk of stroke and heart attack. Prevention of new clots. Resolution of existing clots and prevention of new ones. Prevention of ischemic complications (with aspirin) in unstable angina or NSTEMI. Treatment of acute STEMI, lowering complication risk and improving outcomes. Improved quality of life from fewer serious complications and lower risk of hospitalization, disability, or death.
Frequently Asked Questions
What is the antidote for Lovenox? Protamine sulfate, dosed 1 mg per 1 mg of enoxaparin given in the previous 8 hours. The reversal is incomplete; protamine neutralizes at most roughly 60% of enoxaparin's anti-Xa activity, so watch for ongoing bleeding (StatPearls).
Does enoxaparin need routine lab monitoring? Usually not. Unlike unfractionated heparin, enoxaparin has predictable dosing and does not require aPTT checks. When monitoring is warranted (renal impairment, obesity, pregnancy), an anti-Factor Xa level drawn about 4 hours after the dose is the right test (StatPearls).
Why can't you rub the injection site? Rubbing increases bruising and bleeding into the tissue. Inject subcutaneously at a 90-degree angle, rotate sites, and leave the site alone afterward.
Can Lovenox be used with spinal or epidural anesthesia? Use extreme caution. Enoxaparin around spinal puncture or neuraxial anesthesia carries a risk of spinal or epidural hematoma that can cause lasting paralysis, which is why it is contraindicated in that setting.
What is HIT and why does it matter with Lovenox? Heparin-induced thrombocytopenia is an immune drop in platelets that paradoxically drives clotting. Monitor the platelet count, and if HIT develops, stop the drug. A history of HIT is a contraindication.
How is enoxaparin different from regular heparin? Enoxaparin is a low molecular weight heparin. Its smaller size gives more reliable absorption, a predictable response without routine monitoring, and once- or twice-daily subcutaneous dosing, and it works by inhibiting Factor Xa without needing antithrombin the way unfractionated heparin does.